VRDN•benzinga•
Viridian Therapeutics Earnings Perspective: Return On Capital Employed
Summary
Benzinga Pro data, Viridian Therapeutics (NASDAQ:VRDN) reported Q2 sales of $256 thousand. Earnings fell to a loss of $29.49 million, resulting in a 14.78% decrease from last quarter.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 9, 2022 by benzinga